A pan-cancer multi-omics atlas identifies HTR7 as a neuroimmune modulator associated with macrophage polarization and poor prognosis in AML
Year: 2026
Type: article
Abstract: Serotonin signaling is increasingly implicated in cancer biology, but the role of 5-hydroxytryptamine receptor 7 (HTR7) in tumor growth and macrophage polarization remains poorly defined. We integrated pan-cancer multi-omics data from 33 TCGA tumor types with single-cell and spatial transcriptomics, functional assays, xenograft models, and computational drug screening, focusing on acute myeloid leukemia (AML). HTR7 was upregulated in multiple malignancies and preferentially enriched in monocyte/macrophage populations, with spatial expression overlapping macrophage-rich regions. In clear cell renal cell carcinoma, CellChat predicted TNF- and SPP1–integrin-mediated communication involving HTR7-positive macrophages. HTR7 depletion suppressed proliferation and migration in glioma, breast cancer, and hepatocellular carcinoma cells, reduced Vimentin and SNAI1 expression, and inhibited hepatocellular carcinoma and AML xenograft growth. In AML, elevated HTR7 expression was independently associated with shorter overall survival. HTR7 depletion reduced leukemic cell viability and induced G0/G1 arrest, while RNA sequencing revealed suppression of PI3K/AKT and cell-cycle programs. In primary human monocyte-derived macrophages and THP-1-derived macrophages, HTR7 knockdown impaired IL-4/IL-13-induced M2-like polarization and reduced M2-associated marker expression. In AML cell lines, HTR7 depletion reduced AKT and NF-κB phosphorylation and MRC1 and IL10 expression, whereas SC79 partially reversed these effects. Virtual screening and molecular dynamics simulations identified nilotinib as a candidate HTR7 ligand, and cellular thermal shift assays showed increased HTR7 thermal stability, consistent with intracellular target engagement. Higher HTR7 expression was associated with greater nilotinib sensitivity in BeatAML, whereas HTR7 depletion modestly increased nilotinib IC₅₀ values in AML cells. Together, these findings support HTR7 as a neuroimmune regulator of tumor growth and M2-like macrophage polarization, and as a candidate prognostic biomarker and therapeutic target in AML.
Source: Cell Death Discovery
Authors: Xiumei Xu(Conceptualization, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft), Yuting Li(Conceptualization, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft), Chenyu Jiang(Conceptualization, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft), Xiaoqin Xiong(Conceptualization, Supervision, Validation), Qulian Guo(Methodology, Software, Validation), Xiaoqin Lei(Conceptualization, Data curation, Funding acquisition, Supervision), Yansha Pan(Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing), Fangfang Zhong(Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing)
Institution: Affiliated Hospital of Southwest Medical University
Language: English
Topic: Immune cells in cancer
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: 5-HT7 receptor, serotonin receptors, acute myeloid leukemia, macrophage polarization, M2 macrophages, neuroimmune regulation, tumor microenvironment, nilotinib, PI3K/Akt signaling, NF-κB, prognostic factors, therapeutic target, clear cell renal cell carcinoma, hepatocellular carcinoma, glioma, breast cancer, drug repurposing
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7234166795
